Trastuzumab Current Events | Trastuzumab News | 2
|
|
|
Sort By:
Page Views | Date |
Early-stage, HER2-positive breast cancer patients at increased risk of recurrence
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. view more (2009-11-03)
New Herceptin results confirm impressive reduction in risk of cancer returning
New Herceptin results confirm impressive reduction in risk of cancer returning in women with aggressive form of early-stage breast cancer. view more (2005-09-14)
Breast cancer subtypes linked to survival from secondary brain tumors
Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases. view more (2008-02-28)
OHSU Cancer Institute researchers find connection between protein, prognosis in breast cancer
Oregon Health & Science University Cancer Institute researchers have found that a tumor protein present in an aggressive form of breast cancer is related to a poor prognosis. view more (2008-04-14)
Breast cancer treatment resistance linked to signaling pathway
Activation of the Src signaling pathway may cause resistance to standard medical treatment in some patients with breast cancer, and inhibition of this pathway holds the potential to overcome that resistance, according to data presented here at the American Association for Cancer Research Molecular Diagnostics in Cancer Therapeutic Development... view more... (2008-09-23)
NIST, NCI, SAIC partner on new method for detecting HER2 breast cancer
Generations of mothers have served up chicken soup to remedy the common cold, but now the therapeutic fowl may find use in diagnosis as well. Researchers at the National Institute of Standards and Technology (NIST), the National Cancer Institute (NCI) and the scientific research firm SAIC recently showed how chicken antibodies may one day improve... view more... (2008-02-20)
Analysis of breast-cancer gene role offers promising target
Researchers at UT Southwestern Medical Center have for the first time described how multiple copies of a gene are responsible for metastases in early-stage breast cancer and poor prognosis for patients. view more (2006-10-31)
Primrose oil component cuts levels of cancer-causing gene Her-2/neu
Gamma-linolenic acid (GLA), a substance in evening primrose oil and several other plant oils used in herbal medicine, inhibits action of Her-2/neu, a cancer gene that is responsible for almost 30 percent of all breast cancers. view more (2005-11-02)
Herceptin does not increase heart failure in patients long-term
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31. view more (2007-06-04)
Vaccine against HER2-positive breast cancer offers complete protection in lab
Researchers at Wayne State University have tested a breast cancer vaccine they say completely eliminated HER2-positive tumors in mice - even cancers resistant to current anti-HER2 therapy - without any toxicity. view more (2008-09-15)
Canadian cardiology team clears the way for lifesaving breast cancer treatment
A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society. view more (2009-10-26)
M. D. Anderson study finds change in HER2 status after treatment with Herceptin
Researchers at The University of Texas M. D. Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. view more (2008-09-04)
New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use. view more (2008-04-17)
Study finds cardiac toxicity rates high with herceptin use
The first study to look at "real world" use of Herceptin in advanced breast cancer patients found a higher incidence of cardiac toxicity - 28 percent of patients treated - than clinical trials of the drug have reported to date, but also concluded that the majority of this heart damage could be reversed with treatment. view more (2006-08-15)
|
|
|
|
Sort By:
Page Views | Date |
|
